Today: 29 June 2026
Browse Category

Pfizer News 4 November 2025 - 2 December 2025

PFE Stock Today (Nov. 25, 2025): Pfizer Rises on Metsera Obesity Deal, PADCEV Approval and Options Surge

PFE Stock Today (Nov. 25, 2025): Pfizer Rises on Metsera Obesity Deal, PADCEV Approval and Options Surge

Pfizer shares rose 1.7% to $25.65 by early afternoon Tuesday after the company completed a $10 billion acquisition of obesity-drug developer Metsera. The stock traded between $25.24 and $25.96, with a market cap near $143 billion. Pfizer also reported new FDA approval for PADCEV plus Keytruda in bladder cancer and continued strong options activity at the $25 strike.
25 November 2025
···
Pfizer Stock News Today (PFE): Texas ADHD Settlement, New Antibody Partnership and Obesity Push – November 19, 2025

Pfizer Stock News Today (PFE): Texas ADHD Settlement, New Antibody Partnership and Obesity Push – November 19, 2025

Pfizer and Tris Pharma agreed to pay $41.5 million to settle Texas claims over adulterated ADHD drug Quillivant XR. Pfizer also announced a research deal with Nona Biosciences for antibody discovery. At the Jefferies Healthcare Conference, management reaffirmed $7.7 billion in cost cuts and a push into obesity drugs. PFE traded near $25.37 early Wednesday, slightly down from the prior close.
19 November 2025
····
Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer Stock Today (Nov. 18, 2025): PFE steadies near $25 as Pfizer launches multi‑tranche bond sale to help fund Metsera deal

Pfizer launched a U.S. dollar bond sale aiming to raise at least $5 billion to help fund its recent Metsera acquisition, which closed Nov. 13 for up to $10 billion. The offering may include up to seven tranches, with early talks on a 40-year note at about 125 basis points over Treasuries. Pfizer shares traded near $25.11 as of 16:12 UTC, little changed on the day.
18 November 2025
·····
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Stock Today, November 12, 2025: Shares Nudge Higher as Jefferies Webcast Set, Metsera Deal Stays in Focus

Pfizer shares rose 1.7% to $25.94 Wednesday afternoon, trading in a narrow range ahead of next week’s CFO webcast at the Jefferies London Healthcare Conference. Investors are watching for updates on Pfizer’s $10 billion Metsera obesity-drug deal, with a shareholder vote set for November 13. Pfizer recently raised its 2025 EPS outlook and declared a $0.43 Q4 dividend. Market sentiment improved after positive media commentary.
12 November 2025
···
Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Pfizer (PFE) Stock Today — Nov 7, 2025: Metsera Bidding War Intensifies, Dividend Record Date, and What’s Moving the Share Price

Pfizer shares fell 2.3% to $24.28 amid heavy trading as a Delaware judge allowed Metsera to exit its deal with Pfizer, intensifying the takeover battle with Novo Nordisk. Pfizer is reportedly considering a higher bid ahead of Metsera’s Nov. 13 shareholder vote. The company marked its dividend record date today for a $0.43 payout. Earlier this week, Pfizer raised its 2025 EPS guidance after beating Q3 estimates.
7 November 2025
····
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer Stock’s Wild November Ride: Earnings Beat, Obesity Drug Battle & Bold Forecasts

Pfizer shares traded near $24.60 on Nov. 4, 2025, down about 8–9% year-to-date and over 60% from their 2021 peak. Q3 adjusted earnings beat forecasts at $0.87 per share, but revenue missed slightly at $16.65 billion. Pfizer raised its full-year profit outlook and reaffirmed revenue guidance. The company is locked in a takeover battle with Novo Nordisk for obesity drug developer Metsera.
4 November 2025
·····
1 2

Stock Market Today

  • IMF Research Questions Bonds as Safe Havens in Stock Market Crashes, Suggests Commodities ETFs
    June 28, 2026, 10:12 PM EDT. Recent IMF research reveals that bonds may no longer serve as reliable diversifiers during stock market downturns due to increased positive correlation with stocks since 2019. Traditional wisdom that bonds rise when stocks fall is challenged. Instead, adding commodities like precious metals could offer better portfolio protection. ETFs such as iShares Silver Trust (SLV), which tracks silver bullion and has returned 21.75% annually over five years, and VanEck Rare Earth and Strategic Metals ETF (REMX) provide exposure to these assets. Silver's sharp 147.9% gain in 2025 reflects inflation concerns and industrial demand but also comes with volatility, having dropped 50% since its January peak. Investors should weigh risks carefully when seeking diversification beyond stocks and bonds.

Latest articles

Trump-era loan caps could open door for private lenders in grad school market

Trump-era loan caps could open door for private lenders in grad school market

29 June 2026
July 1 federal loan caps slash Grad PLUS access, forcing many graduate and professional students to seek private loans; Sallie Mae projects up to 70% origination growth over several years, while SoFi reports record student-loan volume—investors now face a real-time test of how much demand shifts to private lenders as federal limits hit.
IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

29 June 2026
IREN Limited (NASDAQ:IREN) plunged 21.3% to $47.21 over five straight down days despite announcing a record $50M+ annual Warriors jersey deal, as investors focused on the company’s not fully contracted $4.4B target ARR and high short interest at 19.74% of float, with Friday’s close near the lowest analyst target.
Go toTop